Altimmune, Inc.

Good morning, ladies and gentlemen, and welcome to the Altamune First Quarter 2025 Financial Results Conference Call. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Advisor to Altamune. Lee, you may begin.

Thanks, Gigi, and good morning, everyone. Once again, thank you all for joining us for Altamune's first quarter 2025 Financial Results and Business Update conference call. On today's call, you'll hear from Dr. Vipengar, our Chief Executive Officer, Dr. Scott Harris, our Chief Medical Officer, and Greg Weaver, our Chief Financial Officer. Dr. Scott Roberts, our chief scientific officer, and Ray George, our chief business officer, are with us for the Q&A session. Our first quarter 2025 results and corporate update press release was issued earlier this morning and can be found on the investor relations section of the Altimmune website. Before we begin, I'd like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altamune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a full review of the risk factors that could affect the company's future results and operations, we refer you to the company's filings with the Securities and Exchange Commission. I'd also direct you to read the forward-looking statement disclaimer in our press release issued this morning, which is now available on the website. Any statements made on this conference call speak only as of today's date, May 13th, 2025. and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that may occur on or after today. As a reminder, this call is being recorded and will be available for audio replay on the Altimmune website. With that said, it's now my pleasure to turn the call over to Dr. Vipin Garg, President and Chief Executive Officer of Altimmune. Vipin.

Thank you, Lee. Good morning, everyone, and thank you for joining us today for our first quarter financial results and corporate update. As you can imagine, we are very excited about the upcoming readout of our IMPACT Phase IIb MASH trial, which we expect to announce this quarter. Based on the class-leading liver fat reduction of pembidutide and the use of biopsy rereads to minimize placebo response, we are confident of achieving the trial's key efficacy and safety objectives. If successful, Pembidutide would become the only improtant to achieve statistical significance on MASH endpoints at only 24 weeks of treatment. Furthermore, it will be the first therapy of any kind to combine these effects with clinically meaningful weight loss at this early time point. If approved, we believe that Pembidutide could provide a complete solution for the treatment of MASH. We announced today that we have entered into a credit facility with Hercules Capital for up to $100 million. This is strategically important as we build upon our balance sheet strength and provide flexibility to support our continued development of Pembidutide. Greg will speak further on our financing later on the call. Our recent R&D day event marked an important milestone in pursuing our vision of pembidutide becoming the treatment of choice in liver and cardiomyocardial diseases. We unveiled our plans for phase two trials in alcohol use disorder, or AUD, and alcohol liver disease, or ALD. Both AUD and ALD are areas of significant unmet medical need with limited treatment options. Pembidutide has the potential to disrupt the treatment paradigm in both these conditions if we are able to demonstrate a reduction in alcohol consumption in combination with an amelioration of fat-induced liver inflammation and fibrosis. This profile of clinical benefits was enthusiastically received by various physician groups and patients. which adds to our conviction for developing pembidutide in these indications. The expansion into these indications demonstrates our commitment to establish pembidutide as a potential foundational treatment across multiple fibrotic liver diseases and their primary causes. With that, I'll now turn the call over to Dr. Scott Harris, our Chief Medical Officer, to provide a clinical development update. Scott? Thank you, Vipin.